Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Xuebijing

Other

Phase 4 Most advanced trial (none active)
1 Registered trials

What is Xuebijing?

Xuebijing is an investigational drug studied in Pulmonary Disease, Chronic Obstructive.

At a glance

Drug type
Other
Therapy area
Respiratory
In trials of
RKTO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02937974 Phase 4 Pulmonary Disease, Chronic Obstructive Unknown RKTO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Disease, Chronic Obstructive

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.